Milestone in Cancer Research: Aurigene Presents Impressive Phase 1 Results

Aurigene Oncology Limited, a subsidiary of Dr. Reddy’s, has presented promising Phase 1 results for India's first novel CAR-T cell therapy, Ribrecabtagene autoleucel, in the fight against multiple myeloma. The groundbreaking treatment achieved an impressive clinical response rate of 100% in patients and showed no serious safety concerns. This track record paves the way for the upcoming Phase 2 study, which has already received approval from regulatory authorities. If the previous results are confirmed, this could represent a significant advancement in treatment options for myeloma patients in India and substantially expand the medical horizon.